More information and detailed protocols for the HaloTag Mammalian Pull-Down and Labeling System (Cat.# G6500) and HaloTag Mammalian Pull-Down System (Cat.# G6504) are available in Technical Manual #TM342
A recent phase 2 trial testing doses of up to 16 mg/week suggests that, while higher doses yield further improvements in blood glucose and body weight, there is no clinical justification for exceeding the approved dose of 2 mg/week due to increased frequency of AEs
2 AllerVie Health, Birmingham, AL, USA
While the majority (62%) dont provide coverage, others are taking or considering a range of actions, from prior authorization to covering the drugs only for members with certain BMIs
HernandezSegura A, Nehme J, Demaria M
Hospitals and clinics often provide similar services